ASX Announcements

For a full list of company announcements visit the ASX website.

3 June 2021	Medgate extends European ResAppDx trial
20 May 2021	Corporate Overview Presentation
18 May 2021	Initial Director's Interest Notice
18 May 2021	Brian Leedman Reappointed as Executive Director
17 May 2021	First participant recruited in COVID-19 cough study
4 May 2021	Agreement with Ilara Health to sell ResAppDx in Kenya
30 April 2021	Quarterly Activities Report and Appendix 4C
29 April 2021	Quarterly Results and Investor Conference Call Notification
21 April 2021	Change in substantial holding
20 April 2021	Ceasing to be a substantial holder
19 April 2021	Appendix 3G
19 April 2021	Section 708A Notice and Appendix 2A
12 April 2021	Proposed issue of Securities
12 April 2021	ResApp secures firm commitments to raise $5.5 million
8 April 2021	Trading Halt
1 April 2021	Appendix 3G
25 March 2021	TGA clearance achieved for wearable
16 March 2021	Change of Director's Interest Notice - Chris Ntoumenopoulos
16 March 2021	Change of Director's Interest Notice - Tony Keating
16 March 2021	Change of Director's Interest Notice - Roger Aston
16 March 2021	Change in substantial holding
12 March 2021	S&P DJI Announces March 2021 Quarterly Rebalance
12 March 2021	Section 708A Notice and Appendix 2A
12 March 2021	ResApp grants SDK licence to AstraZeneca for asthma program
11 March 2021	Clinical study to develop COVID-19 screening test
4 March 2021	Medgate commences European ResAppDx trial
2 March 2021	Proposed issue of Securities - RAP
2 March 2021	CE Mark achieved for wearable device
26 February 2021	Update on Licencing Agreement with WMA
25 February 2021	Resignation of Joint Company Secretary
24 February 2021	Appendix 4D and Half Year Financial Report
10 February 2021	Pre-Submission package lodged with the US FDA
4 February 2021	ResApp receives $801,738 R&D tax incentive refund and grant
2 February 2021	ResApp strengthens patent position in Europe
29 January 2021	Quarterly Activities Report and Appendix 4C
28 January 2021	Quarterly Results and Investor Conference Call Notification
12 January 2021	Appendix 3G
11 January 2021	ResApp appoints VP, Commercial to progress growth strategy

29 December 2020	SleepCheck Launched on Select Android Devices
23 December 2020	ResApp Terminates MOU with RB
22 December 2020	Software updates for ResAppDx to underpin growth
11 December 2020	S&P DJI Announces December 2020 Quarterly Rebalance
4 December 2020	Appointment of Joint Company Secretary
2 December 2020	Change of Director's Interest Notice
2 December 2020	Appendix 3G
26 November 2020	Notification of Change of Auditor
26 November 2020	Adoption of New Constitution
26 November 2020	Results of Annual General Meeting
26 November 2020	Annual General Meeting Presentation
26 November 2020	2020 Letter to Shareholders
24 November 2020	Positive engagement with US FDA following SleepCheck Pre-Sub
19 November 2020	ResAppDx to be integrated into WMA telehealth application
9 November 2020	Medgate to pilot ResAppDx for telehealth across Europe
30 October 2020	Quarterly Activities Report and Appendix 4C
28 October 2020	ResAppDx launched on select Android devices
27 October 2020	Quarterly Results and Investor Conference Call Notification
26 October 2020	Notice of Annual General Meeting/Proxy Form
22 October 2020	AstraZeneca to use new ResApp software in clinical study
21 October 2020	Partners with largest Australian consumer healthcare network
28 September 2020	ResApp Partners with Diabetes Queensland for SleepCheck
21 September 2020	SleepCheck Pre-Submission Package Lodged with the US FDA
1 September 2020	Continued Use of ResAppDx at COVID-19 Respiratory Clinic
31 August 2020	Appendix 4G
31 August 2020	Corporate Governance Statement
31 August 2020	Appendix 4E and Annual Report
4 August 2020	SleepCheck Now Available in 36 Countries
29 July 2020	Quarterly Activities Report and Appendix 4C
24 July 2020	Quarterly Results and Investor Conference Call Notification
17 July 2020	ResApp to Present at ShareCafe Investor Webinar
2 July 2020	Change of Director's Interest Notice
1 July 2020	Section 708A Notice and Appendix 2A
1 July 2020	ResAppDx-EU to be Launched on Phenix Health Telehealth App
1 July 2020	Coviu and ResApp Health Sign Service Agreement
30 June 2020	Ilara and ResApp Announce Evaluation of ResAppDx in Africa
29 June 2020	SleepCheck App for iPhone Now Available on the App Store
29 June 2020	DARPA WASH Program Update
18 June 2020	ResApp Signs MOU to Develop Respiratory App for Consumers
16 June 2020	Phenix and ResApp Sign Software Licensing Agreement
12 June 2020	S&P DJI Announces June 2020 Quarterly Rebalance
8 June 2020	German Health-Economic Evaluation and Update on COPD Study
11 May 2020	ResApp to Present at TechKnow Invest Roadshow Webinar
11 May 2020	ResAppDx-EU in Use at COVID-19 Respiratory Clinic.
11 May 2020	Change in substantial holding
6 May 2020	Section 708A Notice and Appendix 2A
6 May 2020	ResApp Receives Final Design Files for Hardware Devices
30 April 2020	Quarterly Update and Appendix 4C
22 April 2020	Investor Presentation
6 April 2020	Initial Director's Interest Notice
6 April 2020	ResApp Appoints Dr Michael Stein as a Non-Executive Director
1 April 2020	ResApp Announces SleepCheck, a Sleep Apnoea Screening App
30 March 2020	Coviu and ResApp Complete Initial ResAppDx-EU Integration
30 March 2020	Resignation of Non-Executive Director
26 March 2020	ResApp Builds European Market Presence
24 March 2020	ResAppDx-EU to be Deployed on Phenix Health Telehealth App
11 March 2020	Investor Conference Call
11 March 2020	Update on US FDA De Novo Classification Request
11 March 2020	Direct-to-Consumer Product Update
9 March 2020	Trading Halt
28 February 2020	Appendix 4D and Half Year Financial Report
27 February 2020	Section 708A Notice and Appendix 2A
21 February 2020	Proposed issue of Securities
21 February 2020	ResApp Completes $5 Million Capital Raising
20 February 2020	TGA Approval for Adult Respiratory Disease
19 February 2020	Trading Halt
18 February 2020	Proposed issue of Securities
18 February 2020	Functional Testing of Handheld and Wearable Devices Complete
31 January 2020	Quarterly Update and Appendix 4C

20 December 2019	Change of Director's Interest Notice x 4
20 December 2019	Appendix 3B
19 December 2019	Clinical Study of COPD Screening in Indigenous Australians
12 December 2019	ResApp Receives $1.8 Million R&D Tax Incentive Cash Rebate
28 November 2019	Results of Annual General Meeting
28 November 2019	Annual General Meeting Presentation
28 November 2019	ResAppDx-EU to be deployed on the Coviu Telehealth Platform
25 November 2019	2019 Letter to Shareholders
15 November 2019	ResApp Grants Option to Consumer Health Division of Sanofi
30 October 2019	Quarterly Update and Appendix 4C
28 October 2019	Notice of Annual General Meeting
24 October 2019	Change of Registered Office
4 October 2019	ResApp Joins Startup Creasphere Digital Health Program
3 October 2019	Change of Principal Place of Business
2 October 2019	TGA Approval for Paediatric Respiratory Disease Diagnosis
30 September 2019	Positive Results from At-Home Sleep Apnoea Study
26 September 2019	ResAppDx-EU for Adult Respiratory Disease Receives CE Mark
16 September 2019	Investor Presentation September 2019
28 August 2019	Appendix 4G
28 August 2019	Corporate Governance Statement
28 August 2019	Appendix 4E and Annual Report
23 August 2019	ResApp Receives CE Mark for ResAppDx-EU
29 July 2019	Quarterly Update and Appendix 4C
4 July 2019	Appendix 3B and Section 708A Notice
1 July 2019	At-Home Obstructive Sleep Apnoea Study Update
19 June 2019	Extension of CEO and Managing Director's Contract
13 June 2019	Investor Presentation June 2019
12 June 2019	ResApp Receives $1.785 Million R&D Tax Incentive Cash Rebate
6 June 2019	Paediatric Study Published In Peer-Reviewed Journal
5 June 2019	Appendix 3B
5 June 2019	Healthcare Leaders Appointed to Industry Advisory Board
30 May 2019	Market Clarification Announcement
29 May 2019	Customised Hardware and Wearable Devices to Expand ResApp’s Addressable Markets
6 May 2019	Appendix 3B
30 April 2019	Quarterly Update and Appendix 4C
23 April 2019	Positive Results from Australian Adult Clinical Study
15 April 2019	ResApp Submits De Novo Application to the FDA
29 March 2019	Update on Australian Adult Study and FDA De Novo Submission
19 March 2019	TechKnow Invest Roadshow Presentation
18 March 2019	Updated Top-line Results from SMARTCOUGH-C-2 Study
13 March 2019	ResApp Receives R&D Advanced Overseas Finding
28 February 2019	Appendix 4D and Half Year Financial Report
25 February 2019	Appendix 3B
11 February 2019	Appendix 3B
4 February 2019	ResApp to Host Investor Q&A Conference Call
29 January 2019	Quarterly Update and Appendix 4C
2 January 2019	ResApp Submits CE Mark Technical File

15 November 2018	Results of Annual General Meeting
15 November 2018	2018 Letter to Shareholders
14 November 2018	ResApp Clears Major Milestone for CE and TGA with ISO 13485
5 November 2018	ResApp Receives Notice of Allowance for Core Patent in Japan
31 October 2018	Appendix 4C - Quarterly
31 October 2018	CEO's Prepared Statement for Investor Conference Call
30 October 2018	ResApp Presentation at TechKnow Invest Roadshow
30 October 2018	Investor Conference Call
30 October 2018	Positive Preliminary Results from SMARTCOUGH-C-2 Study
29 October 2018	Voluntary Suspension Update
24 October 2018	Voluntary Suspension
22 October 2018	Trading Halt
17 October 2018	Response to ASX Price Query
15 October 2018	Notice of Annual General Meeting 2018
11 October 2018	Positive Results for Prospective Sleep Apnoea Clinical Study
2 October 2018	Recruitment Completed in Prospective Sleep Apnoea Study
28 September 2018	Appendix 4G
28 September 2018	Corporate Governance Statement 2018
28 September 2018	Annual Report 2018
27 September 2018	Change in substantial holding
27 September 2018	ResApp Provides Update on SMARTCOUGH-C-2 Study Timing
24 September 2018	Appendix 3B & Section 708A Notice
19 September 2018	ResApp Successfully Completes $7.5 Million Capital Raising
12 September 2018	Company Update Presentation
3 September 2018	Positive Results for Australian Prospective Paediatric Study
31 August 2018	Trading Halt
31 August 2018	Appendix 4E – Preliminary Final Report
16 August 2018	ResApp Partners with Lockheed Martin for DARPA Research
15 August 2018	Notice of Acceptance Received for Core Patent in Australia
9 August 2018	Broker Meets Biotech Presentation
2 August 2018	Enrolment Completed in Australian Paediatric Clinical Study
1 August 2018	ResApp Completes Enrolment of Smartcough-C-2 Study
31 July 2018	Quarterly Update and Appendix 4C
12 July 2018	ResApp Provides Obstructive Sleep Apnoea Study Update
28 June 2018	ResApp Provides Update on Australian Clinical Study
6 June 2018	ResApp Receives Notice of Allowance for Core Patent in US
31 May 2018	ResApp Provides SMARTCOUGH-C-2 Study Update
30 April 2018	Quarterly Update and Appendix 4C
27 April 2018	Corporate Governance Statement
26 April 2018	ResApp Receives R&D Tax Incentive Cash Rebate for FY17
24 April 2018	ResApp Signs LOI with German Private Hospital Network
16 April 2018	Response to ASX Aware Letter
12 April 2018	Investor Conference Call
10 April 2018	Investor Presentation
10 April 2018	Response to ASX Price Query
10 April 2018	ResApp Develops Obstructive Sleep Apnoea Screening Test
9 April 2018	Trading Halt
9 March 2018	ResApp Provides SMARTCOUGH-C-2 Study Update
9 March 2018	S&P DJ Indices Announces March Quarterly Rebalance
28 February 2018	Appendix 4D and Half Year Financial Report
23 February 2018	Response to ASX Price Query
31 January 2018	Appendix 4C - Quarterly Dec 2017
11 January 2018	SMARTCOUGH-C-2 Receives Third IRB Approval
8 January 2018	ResApp Enrols First Patient in SMARTCOUGH-C-2 Study

29 December 2017	Final Director's Interest Notice
29 December 2017	Initial Director's Interest Notice
29 December 2017	ResApp Appoints Non-Executive Director
19 December 2017	ResApp Receives IRB Approval at Massachusetts General
18 December 2017	Appendix 3B
18 December 2017	Positive Results from Australian Adult Clinical Studies
13 December 2017	ResApp Receives IRB Approval at Texas Children's Hospital
3 November 2017	Results of Annual General Meeting
3 November 2017	AGM CEO and Managing Director's Address to Shareholders
16 October 2017	Appendix 4C - Quarterly Sep 2017
10 October 2017	ResApp to Present at Upcoming Investor Conferences
6 October 2017	Change of Director's Interest Notice
3 October 2017	Notice of Annual General Meeting
29 September 2017	Letter to Shareholders
29 September 2017	Appendix 4G
29 September 2017	Annual Report 2017
22 September 2017	Becoming a substantial holder
20 September 2017	Updated Corporate Governance Policies
14 September 2017	Update on Field Evaluation by Medecins Sans Frontieres
12 September 2017	Investor Presentation
4 September 2017	SMARTCOUGH-C Study and Paediatric Clinical Strategy Update
31 August 2017	Appendix 4E - Preliminary Final Report
23 August 2017	Dr Philip Currie Joins ResApp's Scientific Advisory Board
21 August 2017	ResApp Receives R&D Tax Incentive Cash Refund for FY16
11 August 2017	Change of Director's Interest Notice
9 August 2017	Investor Conference Call
9 August 2017	Reinstatement to Official Quotation
9 August 2017	Preliminary Top-line Results from SMARTCOUGH-C Study
2 August 2017	Voluntary Suspension
31 July 2017	Trading Halt
22 July 2017	Appendix 3B
20 July 2017	Appendix 4C - Quarterly Jun 2017
14 July 2017	Appendix 3B
11 July 2017	Investor Presentation
10 July 2017	Morgans Initiates Research Coverage
30 June 2017	Release of Restricted Securities
22 June 2017	ResApp Provides Updated Australian Paediatric Study Results
22 June 2017	Change in substantial holding
19 June 2017	Completion of Enrolment in SMARTCOUGH-C Study
30 May 2017	ResApp Presentation at ASX Spotlight Investor Conference
30 May 2017	ResApp Provides SMARTCOUGH-C May Study Update
9 May 2017	ResAppDx to be Formally Evaluated by Doctors Without Borders
8 May 2017	Trading Halt
2 May 2017	Extension of CEO and Managing Director's Contract
2 May 2017	Appendix 3B
28 April 2017	ResApp Licenses Additional Pneumonia Diagnostic Tool from UniQuest
28 April 2017	Appendix 4C - Quarterly Mar 2017
23 April 2017	LNK: Change of Perth Address for Shareholder Purposes
19 April 2017	ResApp Extends SMARTCOUGH-C Study
28 March 2017	Change in substantial holding
21 March 2017	ResApp to Present at Upcoming Conferences in March
15 March 2017	ResApp Provides SMARTCOUGH-C Study Update
13 March 2017	Appendix 3B
10 March 2017	S&P DJ Indices Announces March Quarterly Rebalance
1 March 2017	Half Year Report - Note Disclosure Correction
28 February 2017	Appendix 4D and Half Year Accounts
23 February 2017	Change in substantial holding
21 February 2017	ResApp Presentation at the ASX CEO Sessions
14 February 2017	Appendix 3B
30 January 2017	Appendix 4C - Quarterly Dec 2016
10 January 2017	ResApp Announces Expanded Research Collaboration with MGH

16 December 2016	Change of Director's Interest Notice
16 December 2016	Appendix 3B & Section 708A Notice
9 December 2016	ResApp Initiates SMARTCOUGH-C Study in the US
28 November 2016	ResApp to Present at Wilsons Healthcare IT Conference
16 November 2016	Patersons Securities Initiates Research Coverage
16 November 2016	ResApp Receives IRB Approval at Texas Children's Hospital
11 November 2016	Change of Director's Interest Notice x 4
11 November 2016	Appendix 3B
11 November 2016	ResApp Receives IRB Approval at Massachusetts General
9 November 2016	Confirmation of Change of Auditor
2 November 2016	Results of Annual General Meeting
2 November 2016	2016 Letter to Shareholders
28 October 2016	Appendix 4C - Quarterly Sep 2016
27 October 2016	Appendix 3B & Section 708A Notice
25 October 2016	RAP receives Australian Emerging Company of Year Award
21 October 2016	ResApp Receives First Institutional Review Board Approval
18 October 2016	ResApp Investor Presentation
12 October 2016	ResApp Wins Innovation Excellence Award at Tech23 2016
7 October 2016	Appendix 3B & Section 708A Notice
4 October 2016	Notice of Annual General Meeting
3 October 2016	Further Positive Results From Adult Clinical Study
29 September 2016	Trading Halt
28 September 2016	Appendix 4G
28 September 2016	Annual Report 2016
16 September 2016	Appendix 3B & Section 708A Notice
15 September 2016	ResApp Begins Evaluation with Humanitarian Organisation
9 September 2016	Change in substantial holding
31 August 2016	Appendix 4E - Preliminary Final Report
19 August 2016	ResApp Wins Global Grand Finals at Talent Unleashed Awards
18 August 2016	ResApp Expands into Management of Respiratory Disease
4 August 2016	Change of Auditor
29 July 2016	Appendix 4C - Quarterly Jun 2016
29 July 2016	Bioshares Biotech Summit Presentation
22 July 2016	Section 708A Notice
22 July 2016	Appendix 3B
22 July 2016	ResApp Wins Category at the 2016 Talent Unleashed Awards
20 July 2016	Massachusetts General Hospital for US Clinical Study Site
20 July 2016	Becoming a substantial holder
15 July 2016	Appendix 3B
7 July 2016	Ceasing to be a substantial holder
7 July 2016	Appendix 3B
7 July 2016	Response to ASX Price and Volume Query
30 June 2016	Update on US Clinical Study
28 June 2016	Appendix 3B
21 June 2016	Positive Preliminary Results from Adult Clinical Study
20 June 2016	Trading Halt
10 June 2016	Release of Restricted Securities
10 June 2016	Appendix 3B
7 June 2016	ResApp Provides Australian Adult Study Enrolment Update
2 June 2016	Appendix 3B - Exercise of Options
2 June 2016	Appendix 3B - Release of Restricted Securities
18 May 2016	Release of Restricted Securities
18 May 2016	Appendix 3B
3 May 2016	Investor Presentation
29 April 2016	Appendix 4C - Quarterly Mar 2016
29 April 2016	Appendix 3B and Issue of Cleansing Prospectus
28 April 2016	Cleansing Prospectus
20 April 2016	ResApp Completes Oversubscribed $12.5M Capital Raising
5 April 2016	TechKnow Invest Roadshow 2016 Presentation
31 March 2016	ResApp Provides Updated Paediatric Clinical Study Results
23 March 2016	Director Resignation and Appendix 3Z
18 March 2016	Change of Director's Interest Notice
17 March 2016	Response to ASX Aware Query
15 March 2016	ResApp Presentation at the ASX CEO Sessions
14 March 2016	ResApp Completes Successful Pre-Submission Meeting with the US FDA
11 March 2016	Terms of Executive Appointment
11 March 2016	Response to ASX Price and Volume Query
7 March 2016	ResApp Collaborates with Leading Humanitarian Organisation
2 March 2016	ResApp Achieves Breakthrough Performance in Paediatric Clinical Study
1 March 2016	Appendix 4D and Half Year Accounts
26 February 2016	Second Site Added to Adult Clinical Study
24 February 2016	Initial Director's Interest Notice
22 February 2016	ResApp Appoints New Director
18 February 2016	Investor Presentation
11 February 2016	Appendix 3B
29 January 2016	Appendix 4C - Quarterly Dec 2015
27 January 2016	Change in substantial holding
22 January 2016	Appendix 3B
22 January 2016	Conversion of Options and Issue of Cleansing Prospectus
22 January 2016	Cleansing Prospectus
22 January 2016	ResApp to Exhibit at Digital Healthcare Conference in Dubai

31 December 2015	ResApp Files Pre-Submission Package with the US FDA
14 December 2015	ResApp Receives Approval to Begin Adult Study
4 December 2015	Release of Restricted Securities
30 November 2015	Results of Annual General Meeting
25 November 2015	CEO Presentation at Canary Networks Investor Roadshow
16 November 2015	Becoming a substantial holder
11 November 2015	US Roadshow - Investor Presentation
10 November 2015	Further Positive Preliminary Results from Clinical Study
4 November 2015	Exhibitor at McKinsey Global Integrated Care Conference
30 October 2015	Appendix 4C - Quarterly Sep 2015
28 October 2015	Notice of Annual General Meeting/Proxy Form
22 October 2015	Dr Abeyratne to present at Pneumonia Innovations Summit
20 October 2015	TechKnow Invest Roadshow Presentation
12 October 2015	Appendix 3Y – Change of Director’s Interest Notice
6 October 2015	Australia Biotech Invest Presentation
1 October 2015	Appendix 4G
1 October 2015	Annual Report 2015

ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000

LEGAL
Website Terms of Use
Privacy Policy

© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.